Julia M L Brotherton
Overview
Explore the profile of Julia M L Brotherton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
148
Citations
2414
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brotherton J, Brotherton J, Vajdic C, Nightingale C
Expert Rev Pharmacoecon Outcomes Res
. 2025 Jan;
1-20.
PMID: 39783967
Introduction: Cervical cancer is almost entirely preventable by vaccination and screening. Population-based vaccination and screening programs are effective and cost effective, but millions of people do not have access to...
2.
Jennett C, Smith M, Machalek D, Sultana F, Prang K, McDermott T, et al.
J Low Genit Tract Dis
. 2024 Dec;
29(1):13-22.
PMID: 39704438
Objective: In 2017, Australian's National Cervical Screening Program changed from 2-yearly cytology to 5-yearly primary human papillomavirus (HPV) testing. The Stakeholder Opinions of Renewal Implementation and Experiences Study (STORIES) aimed...
3.
Velentzis L, Egger S, Waller J, Jennett C, Brotherton J, Smith M, et al.
Prev Med Rep
. 2024 Sep;
45:102849.
PMID: 39220611
Objective: The coronavirus pandemic impacted health-seeking behaviour and access to primary care in Australia. We investigated factors associated with intention-to-attend and attendance of cervical screening during the pandemic, mainly in...
4.
Colling A, Creagh N, Gogia N, Wyatt K, Zammit C, Brotherton J, et al.
Health Expect
. 2024 Aug;
27(1):e13961.
PMID: 39102732
Background: In July 2022, self-collection became universally available as part of Australia's National Cervical Screening Program. This change aims to address screening inequities experienced among underscreened populations, including women of...
5.
Zammit C, Brooks A, Brotherton J, Nightingale C
Sex Health
. 2024 Jun;
21.
PMID: 38833543
Background In mid-2022 Australia's National Cervical Screening Program made self-collection of a vaginal sample an option for screening for young women or people with a cervix aged 25 to 29...
6.
Palmer M, Saito E, Katanoda K, Sakamoto H, Hocking J, Brotherton J, et al.
Lancet Reg Health West Pac
. 2024 Feb;
44:101018.
PMID: 38404421
Background: The Japanese 2020 cervical screening guidelines recommend conventional cervical cytology screening every 2-years for women aged 20-69 years. The nonavalent human papillomavirus (HPV) vaccine has also recently been approved...
7.
Velentzis L, Smith M, Killen J, Brotherton J, Guy R, Canfell K
Elife
. 2023 Oct;
12.
PMID: 37831501
COVID-19 disrupted school attendance in many countries, delaying routine adolescent vaccination against human papillomavirus (HPV) in some settings. We used , a dynamic model simulating HPV transmission, natural history, vaccination,...
8.
Palmer M, Katanoda K, Saito E, Acuti Martellucci C, Tanaka S, Ikeda S, et al.
Vaccine
. 2023 Sep;
41(41):6135.
PMID: 37659892
No abstract available.
9.
Oommen A, Basu P, Cherian A, Zomawia E, Manoharan R, Pricilla R, et al.
Implement Sci Commun
. 2023 Jun;
4(1):62.
PMID: 37291627
Background: In view of the WHO's call for the elimination of cervical cancer as a public health problem, and current low screening coverage, Indian policy makers need evidence on how...
10.
Brotherton J, McDermott T, Smith M, Machalek D, Shilling H, Prang K, et al.
Prev Med Rep
. 2023 May;
33:102213.
PMID: 37223565
In this study, we aimed to document stakeholders' experiences of implementing Australia's renewed National Cervical Screening Program. In December 2017, the program changed from 2nd yearly cytology for 20-69 year...